Cetuximab is widely used to treat HNSCC, yet therapy is not individualised based on EGFR expression, unlike for EGFR inhibitors in other cancers, since EGFR copy number does not act as a predictive biomarker for the efficacy of cetuximab in HNSCC [26]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.